NCT03940703 2026-02-27A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)EMD SeronoPhase 2 Active not recruiting140 enrolled 47 charts
NCT02864992 2025-12-23Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)EMD SeronoPhase 2 Active not recruiting337 enrolled 13 charts 2 FDA
NCT04515394 2022-12-22Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)EMD SeronoPhase 2 Terminated3 enrolled 6 charts